Over 130 million doses have already been administered worldwide. It’s early days, but the signs are promising in places like Israel and the UK.
Tamara Dus, director of University Health Network Safety Services, administers a Pfizer-BioNTech COVID-19 vaccine in Toronto.
THE CANADIAN PRESS/Frank Gunn
The arrival of COVID-19 vaccines has raised hope for an end to the pandemic. Hopefully that’s true, but there are variables. Here are some factors that could affect the success of the vaccine rollout.
Clinical trials with human volunteers done in South Africa must get approval from the health products regulator.
Felix Dlangamandla/Beeld/Gallo Images via Getty Images
Advocates for medicines that are unregistered in South Africa have accused the regulatory authority of not being proactive in bringing such products to market and approving their use.
National Institute of Allergy and Infectious Diseases/AP/AAP
These variants are definitely cause for concern. But there’s every indication we can adapt our vaccine strategy to combat these and other variants going forward.
A health-care worker prepares a dose of the Pfizer-BioNTech COVID-19 vaccine at a UHN COVID-19 vaccine clinic in Toronto on Thursday, January 7, 2021.
THE CANADIAN PRESS/Nathan Denette
Behind Canada’s current COVID-19 vaccine shortage is a decades-long tale of unheeded warnings, missed opportunities and dismantled resources that was never going to end well.
A man fills out an online application during a job fair hosted by the city of Chicago in July 2012. The fair offered computer access to people who do not have internet access.
Scott Olson/Getty Images
Americans with excess weight and obesity have been hit hard by COVID-19. Now there is reason to believe they may not get the same protection from the vaccines.
Vaccine selfies are just the tip of the iceberg of doctor frustration over Canada’s fragmented vaccine rollout.
Nigeria can resuscitate its vaccine production laboratory with money recently released by its government for local production of COVID-19 vaccine.
Leon Neal/Getty Images
Giving money to support local production of COVID-19 vaccines is a step in the right direction if it will help in resuscitating Nigeria’s vaccine production laboratory.
Michael Plank, University of Canterbury and Shaun Hendy, University of Auckland, Waipapa Taumata Rau
A new study argues for selective border relaxations. But with COVID-19 more prevalent now than at almost any point in the past, the risk would be substantial.
Researchers are already working to improve the current crop of mRNA vaccines. Hopefully this will help them become more practical and affordable for the entire world, not just first-world countries.
The approval of the first of four COVID-19 vaccines marks the first step in New Zealand’s plans for a Pacific-wide immunisation rollout.
Health workers are preparing COVID-19 vaccine Sinovac during first stage vaccination in Health Center, South Tagerang City, Indonesia, Januari 15, 2021. More than 8.000 health workers there are vacinnated.
ANTARA FOTO/Fauzan/foc
By prioritising vaccination for the elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amid a limited vaccine supply during the first vaccination phase.
Study shows that the Novavax vaccine is effective against the dominant variant of COVID-19 in South Africa.
Jakub Porzycki/NurPhoto via Getty Images
The results indicate that the vaccine efficacy in the UK was 89% for individuals who received at least two doses of vaccine. In South Africa, the vaccine efficacy was 60% in people without HIV.
A recommendation from a German vaccine advisory body not to give the AstraZeneca vaccine to people aged over 65 has caused concern. But we should interpret this advice with caution.
European Conmmission president Ursula von der Leyen is hitting out at AstraZeneca.
EPA/Olivier Hoslet
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute